PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-24.09%
Cash & equivalents declining -24.09% while Biotechnology shows -4.28% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-24.09%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of -6.89%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.04%
Current assets growth ≥ 1.5x the Biotechnology median of -6.05%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-17.11%
PP&E growth below half of Biotechnology median of 0.00%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.78%
≥ 1.5x the Biotechnology median of -0.01%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
≥ 1.5x the Biotechnology median of -4.40%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
86.42%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-55.20%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
21.67%
Above 1.5x Biotechnology median of 2.53%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.67%
Above 1.5x Biotechnology median of 1.02%. Jim Chanos suspects an alarming rise in overall leverage.
0.96%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-5.35%
1.25-1.5x Biotechnology median of -4.59%. Mohnish Pabrai notes above-average reinvested earnings.
-15.38%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
≥ 1.5x Biotechnology median of -6.91%. Joel Greenblatt sees stronger equity growth vs. peers.
-19.98%
≥ 1.5x Biotechnology median of -4.56%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
23.76%
Above 1.5x Biotechnology median 5.60%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.